Document:

Exhibit
10.134

 

[NEITHER THIS SECURITY
NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.][1]

 

SERIES [A/B/C] COMMON STOCK PURCHASE
WARRANT

 

rENNOVA
HEALTH, INC.

 

Warrant Shares: _______                                                                                      Initial Exercise Date: March
__, 2017

 

THIS SERIES [A/B/C] COMMON
STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close
of business on the _____[2] year anniversary
of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from
Rennova Health, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment
hereunder, the “Warrant Shares”) of Common Stock [;provided, however, the exercisability of this
Series C Warrant shall vest ratably from time to time in proportion to the Holder’s (or its permitted assigns) exercise of
the Series B Common Stock Purchase Warrant as compared with all Series B Common Stock Purchase Warrants issued to Holder at the
Closing (“Vesting Schedule”). Notwithstanding anything herein to the contrary, if the Holder exercises all of
its Series B Common Stock Purchase Warrants issued at Closing, all Series C Common Stock Purchase Warrants hereunder may be exercised
by the Holder, if the Holder exercises half of the Series B Common Stock Purchase Warrant issued at Closing, only half of the Series
C Common Stock Purchase Warrants hereunder may be exercised by the Holder until such time that the Holder exercises additional
Series B Common Stock Purchase Warrants.][3]
.. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section
2(b).

 

 

 

 

 

[1]
       Remove legend for Series H Exchange Warrants

[2]
       Series A and C – 5 years; Series B – 18 months

[3]        Series
C only

 

    	 	1	 

     

    

 

 

 

Section 1.Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain [Securities Purchase
Agreement (the “Purchase Agreement”)][Securities Exchange Agreement (the “Exchange Agreement”)],
dated as of March ___, 2017, among the Company and the purchasers signatory thereto.

 

Section 2.Exercise.

 

a)              
Exercise of Warrant. [Subject to the Vesting Schedule,][4]
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company or the Transfer Agent (or such other
office or agency that the Company may designate by notice in writing to the registered Holder at the address of the Holder appearing
on the books of the Company), as applicable, of a duly executed facsimile copy or PDF copy submitted by electronic (or e-mail attachment)
of the Notice of Exercise in the form annexed hereto (“Notice of Exercise”). Within the earlier of (i) three
(3) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein)
following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in
the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of
the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of
Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the
Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee,
by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase
of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may
be less than the amount stated on the face hereof.

 

b)              
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be [_____][5],
subject to adjustment hereunder (the “Exercise Price”).

 

 

 

 

 

 

 

[4]
Series C only

[5] Series A and C - $1.95;
Series B - $1.66

 

    	 	2	 

     

    

 

 

 

c)              
Cashless Exercise. If [at any time after the six-month anniversary of the Closing Date,][6]
there is no effective Registration Statement registering, or no current prospectus available for, the resale of the Warrant Shares
by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)]
by (A), where:

 

		(A)	as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that
is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of
“regular trading hours” (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws)
on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of
the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed and delivered
during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter pursuant to Section
2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading
Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular
trading hours” on such Trading Day;

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) =
the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.  The Company agrees not to
take any position contrary to this Section 2(c).

 

[If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.  The
Company agrees not to take any position contrary to this Section 2(c).][7]

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock
are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.

 

 

 

 

 

 

[6]
Remove for Series H exchange Warrants, reduce period for debenture exchange warrants.

[7] Use this on Series H exchange
warrants instead of language above.

 

    	 	3	 

     

    

 

 

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Purchasers of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees
and expenses of which shall be paid by the Company.

 

Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).

 

		d)	Mechanics of Exercise.

 

i.         
Delivery of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or
resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule 144 (assuming cashless exercise), and otherwise by physical delivery of a certificate, registered
in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the
Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that
is the earlier of (A) the earlier of (i) three (3) Trading Days after the delivery to the Company of the Notice of Exercise and
(ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (B) the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share
Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date
of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
exercise) is received within the earlier of (i) three Trading Days and (ii) the number of Trading Days comprising the Standard
Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the
Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash,
as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the
Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth
Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such
Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement
Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

 

 

    	 	4	 

     

    

 

 

 

ii.                 
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver
to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
which new Warrant shall in all other respects be identical with this Warrant.

 

iii.              
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.              
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights
available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance
with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after
such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for
the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the
Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order
giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the
Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed
rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied
with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price
giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be
required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.

 

v.              
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

vi.              
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses
shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it
for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any
Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for same-day electronic delivery of the Warrant Shares.

 

 

 

    	 	5	 

     

    

 

vii.              
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

e)       Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution
Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon
the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the
61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall
apply to a successor holder of this Warrant.

 

 

 

    	 	6	 

     

    

 

f)               
Issuance Restrictions. Notwithstanding anything herein to the contrary, if the Company has not obtained Shareholder
Approval, then the Company may not issue upon exercise of this Warrant a number of shares of Common Stock, which, when aggregated
with any shares of Common Stock issued (i) pursuant to the conversion of any Debentures, (ii) upon exercise of this or any other
Warrant issued pursuant to the [Purchase Agreement][Exchange Agreement], and (iii) [in connection with the conversion or exercise
of any original issue discount convertible debentures and Common Stock purchase warrants issued pursuant to the [Purchase Agreement][Exchange
Agreement]] (such securities, collectively, the “Issuance Capped Securities” and the holders of Issuance Capped
Securities, the “Capped Holders”) would exceed ______________[8],
subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of the [Purchase Agreement][Exchange Agreement] (such number of shares, the “Issuable
Maximum”). Each Capped Holder shall be entitled to a portion of the Issuable Maximum equal to the quotient obtained by
dividing (x) the Holder’s original Subscription Amount plus the exchange amounts exchanged pursuant to the Exchange Agreement,
if any, by (y) the aggregate original Subscription Amount (or exchange amounts if pursuant to the Exchange Agreement) of all Capped
Holders. In addition, a Capped Holder may allocate its pro-rata portion of the Issuable Maximum among Issuance Capped Securities
held by it in its sole discretion. Such portion shall be adjusted upward ratably in the event a Capped Holder no longer holds any
Issuance Caped Securities and the amount of Issuance Capped Securities issued to such Capped Holder was less than such Capped Holder’s
pro-rata share of the Issuable Maximum. For avoidance of doubt, unless and until any required Shareholder Approval is obtained
and effective, warrants issued to any registered broker-dealer as a fee in connection with the Securities issued pursuant to the
Purchase Agreement as described in clause (iii) above shall provide that such warrants shall not be allocated any portion of the
Issuable Maximum and shall be unexercisable unless and until such Shareholder Approval is obtained and effective.

 

Section 3.Certain
Adjustments.

 

a)              
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

 

 

 

 

 

[8]        19.99%
of the number of shares of Common Stock outstanding on the Trading Day immediately preceding the date of the Purchase Agreement

 

    	 	7	 

     

    

 

b)               Subsequent
Equity Sales. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is
outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or
issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock
Equivalents, at an effective price per share less than the Exercise Price then in effect (such lower price, the
“Base Share Price” and such issuances collectively, a “Dilutive Issuance”) (it being
understood and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether
by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise,
or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive
shares of Common Stock at an effective price per share that is less than the Exercise Price, such issuance shall be deemed to
have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price), then
simultaneously with the consummation of each Dilutive Issuance the Exercise Price shall be reduced and only reduced to equal
the Base Share Price, and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise
Price payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to  the aggregate
Exercise Price prior to such adjustment, provided that the Base Share Price shall not be less than $0.39, not subject to
adjustment for reverse stock splits and the like. Such adjustment shall be made whenever such Common Stock or Common Stock
Equivalents are issued. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 3(b)
in respect of an Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day following
the issuance or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 3(b), indicating
therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms
(such notice, the “Dilutive Issuance Notice”). For purposes of clarification, whether or not the Company
provides a Dilutive Issuance Notice pursuant to this Section 3(b), upon the occurrence of any Dilutive Issuance, the Holder
is entitled to receive upon exercise a number of Warrant Shares based upon the Base Share Price regardless of whether the
Holder accurately refers to the Base Share Price in the Notice of Exercise. If the Company enters into a Variable Rate
Transaction, despite the prohibition thereon in the [Purchase Agreement][Exchange Agreement], the Company shall be deemed to
have issued Common Stock or Common Stock Equivalents at the lowest possible conversion or exercise price at which such
securities may be converted or exercised.

 

c)              
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be
entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d)              
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record
is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock
are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder's
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the
Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of
Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for
the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).

 

 

 

    	 	8	 

     

    

 

e)              
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
(without regard to any limitation in Section 2(e) or Section 2(f) on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in Section 2(e) or Section 2(f) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of
a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion
of this Warrant on the date of the consummation of such Fundamental Transaction. “Black Scholes Value” means
the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg,
L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing
purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility
equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately
following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation
shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date. The payment of the Black Scholes Value will be made by wire
transfer of immediately available funds within five Business Days of the Holder’s election (or, if later, on the effective
date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under
this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares
of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose
of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which
is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.

 

 

 

    	 	9	 

     

    

 

f)               
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)              
Notice to Holder.

 

i.         
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3,
the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.         
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock
is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile
or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date
on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such
notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

Section 4.Transfer
of Warrant.

 

a)              
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section
4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement and the applicable provisions of the Exchange Agreement,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder
delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith,
may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

 

 

    	 	10	 

     

    

 

b)              
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

c)              
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)              
[Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this
Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under
the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale
restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing
such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of
the Purchase Agreement and applicable provisions of the Exchange Agreement.

 

e)              
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring
this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.][9]

 

 

 

 

 

[9] Remove for Series H Warrants.

 

    	 	11	 

     

    

 

 

 

Section 5.Miscellaneous.

 

a)              
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3.

 

b)              
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

 

c)              
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

d)              
Authorized Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e)              
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the [Purchase Agreement][Exchange Agreement].

 

f)               
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)              
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

 

 

 

 

    	 	12	 

     

    

 

 

h)              
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the [Purchase Agreement][Exchange Agreement].

 

i)               
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.

 

j)               
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)              
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)               
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.

 

m)            
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)              
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

 

********************

 

 

(Signature Page Follows)

 

 

 

    	 	13	 

     

    

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

 

	 	
        RENNOVA HEALTH, INC.

	 	 
	 	 
	 	
        By:__________________________________________

        Name: Seamus Lagan

        Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

    	 	14	 

     

    

 

 

NOTICE OF EXERCISE

 

To:rennova
health, inc.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Payment shall take the form of (check applicable box):

 

[_] in lawful
money of the United States; or

 

[_] if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)  
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to
the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor.
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: ________________________________________________________________________

Signature of Authorized Signatory of
Investing Entity: _________________________________________________

Name of Authorized Signatory: ___________________________________________________________________

Title of Authorized Signatory: ____________________________________________________________________

Date: ________________________________________________________________________________________

 

 

 

 

    	 	15	 

     

    

 

EXHIBIT B

 

ASSIGNMENT
FORM

(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please Print)
	 	 
	Address:	 
	 	(Please Print)
	 	 
	
        Phone Number:

         

        Email Address:

         
	
        

        ______________________________________

         

        ______________________________________

	Dated: _______________ __, ______	 
	 	 
	Holder’s Signature:                                         	 
	 	 
	Holder’s Address:                                         	 

 

 

 

 

 

    	 	16Exhibit 10.138

 

Rennova
Health, Inc.

400 S. Australian Avenue, Suite 800

West
Palm Beach, FL 33401

 

March
20, 2017

 

TCA
Global Credit Master Fund LP

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169

 

Re.Securities Purchase Agreement, dated
as of May 31, 2015, as amended

 

Sir/Madam:

 

Reference is hereby
made to that certain Securities Purchase Agreement, dated as of May 31, 2015 (as amended and as may hereafter be amended or restated
from time to time, the “Purchase Agreement”), made by and among: (i) Medytox Solutions, Inc. (the “Company”),
(ii) Health Technology Solutions, Inc., a corporation incorporated under the laws of the State of Florida, Medytox Institute of
Laboratory Medicine, Inc., a corporation incorporated under the laws of the State of Florida, Medical Billing Choices Inc., a
corporation incorporated under the laws of the State of North Carolina, Medytox Diagnostics, Inc., a corporation incorporated
under the laws of the State of Florida, Medytox Medical Marketing & Sales, Inc., a corporation incorporated under the laws
of the State of Florida, PB Laboratories, LLC, a limited liability company organized and existing under the laws of the State
of Florida, Biohealth Medical Laboratory Inc., a corporation incorporated under the laws of the State of Florida, Alethea Laboratories,
Inc., a corporation incorporated under the laws of the State of Texas, International Technologies, LLC, a limited liability company
organized and existing under the laws of the State of New Jersey, EPIC Reference Labs, Inc., a corporation incorporated under
the laws of the State of Florida, Clinlab, Inc., a corporation incorporated under the laws of the State of Florida, Medical Mime,
Inc., a corporation incorporated under the laws of the State of Florida, Epinex Diagnostics Laboratories, Inc., a corporation
incorporated under the laws of the State of California, Epinex Diagnostics Laboratories, Inc., a corporation incorporated under
the laws of the State of Nevada, and Platinum Financial Solutions, LLC, a limited liability company organized and existing under
the laws of the State of Florida (each a “Guarantor” and collectively the “Guarantors” and
together with Company, the “Credit Parties”), and (iii) TCA Global Credit Master Fund, LP, a limited partnership
organized and existing under the laws of the Cayman Islands, (the “Buyer”), pursuant to which Buyer agreed
to purchase from the Company, and the Company agreed to sell and issue to the Buyer, up to Six Million and No/100 United States
Dollars (US$6,000,000.00) of senior secured, convertible, redeemable debentures (the “Debenture(s)”). Except
as otherwise defined herein, terms defined in the Purchase Agreement shall have the same meaning when used herein. The Credit
Parties and the Buyer shall be referred to herein as the “Parties”.

 

By their execution hereof, and for good
and valuable consideration, the receipt of which is hereby acknowledged, the undersigned hereby acknowledge and agree:

 

		1.	the Company shall make a payment of Seven Hundred Fifty Thousand and No/100
United States Dollars (US$750,000) on the date hereof and such amount shall be credited towards the Company’s outstanding
obligations, pursuant to the terms and conditions contained in the Purchase Agreement and the Debentures;

 

		2.	the Company hereby acknowledges and agrees that One Hundred Fifty Thousand
and No/100 United States Dollars (US$150,000) (the “Service Fee”) is due and owing under and pursuant to that
certain Investment Banking Services letter agreement, dated March 20, 2017, made by and among Buyer and Company (in the form attached
hereto as Exhibit A, the “Services Agreement”) and that the Buyer would not enter into this letter agreement
or the Intercreditor Agreement (in the form attached hereto as Exhibit B, the “Intercreditor Agreement”)
but for the execution of the Services Agreement by the Company and the agreement by the Company to pay the amounts provided therein;

 

 

 

 

    	 	1	 

     

    

 

		3.	the Company hereby agrees that, notwithstanding anything which may be contained
in the Services Agreement to the contrary, the Service Fee shall be due and owing in full in cash and without demand on that date
which is the earlier of: (i) six (6) months following the date hereof or (ii) the immediately subsequent date when any registration
statement which may have been previously filed or which may hereafter be filed by the Company becomes effective with the United
States Securities and Exchange Commission.

 

		4.	upon receipt of the funds provided in part (1), notwithstanding anything
which may be contained to the contrary in the Purchase Agreement, any outstanding Debentures or the Transaction Documents, the
Company agrees that it shall make the payments specified on the amortization schedule attached hereto as Schedule A; and

 

		5.	the Company hereby acknowledges and agrees that Section 2.26 of the Purchase
Agreement (definition of “Obligations”) shall include, but shall not be limited to, the obligations provided in this
letter agreement and the Services Agreement.

 

As a condition precedent to the effectiveness of this
letter agreement:

 

		1.	the Credit Parties shall deliver an original copy of this letter agreement,
the Services Agreement, the Intercreditor Agreement, the Guarantee Agreement (in the form attached hereto as Exhibit C,
the “Guarantee Agreement”), and the Security Agreement (in the form attached hereto as Exhibit D, the
“Security Agreement”) to the Buyer;

 

		2.	the Credit Parties shall deliver a copy of the resolutions of its respective
Boards of Directors authorizing the execution of this letter agreement, the Services Agreement, the Intercreditor Agreement, the
Security Agreement, and the Guarantee Agreement to the Buyer; and

 

		3.	the Credit Parties shall pay to Buyer’s counsel, as a legal fee in
consideration for the preparation and negotiation of this letter agreement, the Services Agreement, the Intercreditor Agreement,
the Security Agreement, and the Guarantee Agreement and all transaction documents executed and reviewed in connection herewith
and therewith, immediately upon the execution hereof, Fifteen Thousand
Dollars ($15,000) plus disbursements, costs and expenses.

 

Other than as disclosed
to the Buyer in writing, each of the Credit Parties hereby confirms and affirms that all representations and warranties made by
each of them under the Purchase Agreement and all other Transaction Documents are true, correct and complete as of the date hereof,
and hereby confirms and affirms that all such representations and warranties remain true, correct and complete as of the date hereof,
and by this reference, the Credit Parties do hereby re- make each and every one of such representations and warranties herein as
of the date hereof, as if each and every one of such representations and warranties was set forth and re-made in its entirety in
this letter agreement by each of the Credit Parties.

 

Each of the Credit Parties
hereby affirms its respective Obligations to the Buyer under all of the Transaction Documents and each agrees and affirms as follows:
(i) that as of the date hereof, the Credit Parties, respectively and as applicable, with the exception of any defaults which are
existing as of the date hereof, have each performed, satisfied and complied in all material respects with all the covenants, agreements
and conditions under the Purchase Agreement and each of the Transaction Documents to be performed, satisfied or complied with by
the Credit Parties, as applicable; (ii) that the Credit Parties shall continue to perform each and every covenant, agreement and
condition set forth in the Purchase Agreement and each of the Transaction Documents, and continue to be bound by each and all of
the terms and provisions thereof and hereof; (iii) other than as disclosed to the Buyer prior to the date hereof, that as of the
date hereof, no default or Event of Default has occurred or is continuing under the Purchase Agreement or any other Transaction
Documents, and no event has occurred that, with the passage of time, the giving of notice, or both, would constitute a default
or an Event of Default under the Purchase Agreement or any other Transaction Documents; and (iv) that as of the date hereof, no
event, fact, or other set of circumstances has occurred which could reasonably be expected to have a Material Adverse Effect.

 

Upon receipt of
the $765,000 payable by the Company (consisting of the upfront payment toward the outstanding balance owing to the Buyer and $15,000
owing to Buyer’s counsel), the Buyer hereby acknowledges that the Company shall not be in default of the Purchase Agreement
or any other Loan Document or Transaction Document as a result of any failure to make any required payment prior to the date hereof
and that the Buyer hereby waives any such default which may exist as of the date hereof. The Buyer also acknowledges that the
Notice of Default dated November 3, 2016 has been withdrawn and is of no force or effect.

 

 

 

 

    	 	2	 

     

    

 

Each of the
Credit Parties hereby acknowledges, represents, warrants and confirms to Buyer that: (i) each of the Transaction Documents
executed by the Credit Parties, respectively and as applicable, are valid and binding obligations of the Credit Parties,
respectively and as applicable, enforceable against each of them in accordance with their respective terms; (ii) all other
Obligations of the Credit Parties shall be and continue to be and remain secured by and under the Transaction Documents and
all UCC-1 Financing Statements filed in connection therewith; (iii) there are no defenses, setoffs, counterclaims,
cross-actions or equities in favor of the Credit Parties to or against the enforcement of any of the Transaction Documents,
and to the extent any of the Credit Parties have any defenses, setoffs, counterclaims, cross-actions or equities against the
Buyer and/or against the enforceability of any of the Transaction Documents, each of the Credit Parties acknowledges and
agrees that same are hereby fully and unconditionally waived by each of the Credit Parties; and (iv) no oral representations,
statements, or inducements have been made by Buyer, or any agent or representative of Buyer, with respect to the Purchase
Agreement or any other Transaction Documents.

 

The Credit Parties each hereby
represents, warrants and covenants as follows: (i) that the Buyer’s security interests in all of the “Collateral”
(as such term is defined in the Security Agreements) are and remain valid, perfected, first-priority security interests in such
Collateral (subject only to the Intercreditor Agreement), respectively and as applicable, and the Credit Parties have not granted
any other Liens or security interests of any nature or kind in favor of any other Person affecting any of such Collateral, except
as provided in the Intercreditor Agreement.

 

As of the date hereof, the
Credit Parties each hereby acknowledge and admit that: (i) the Buyer has acted in good faith and has fulfilled and fully performed
all of its obligations under or in connection with the Purchase Agreement or any other Transaction Documents; and (ii) that there
are no other promises, obligations, understandings or agreements with respect to the Purchase Agreement or the Transaction Documents,
except as expressly set forth herein.

 

The Credit Parties each hereby
represent and warrant to the Buyer that the execution and delivery by the Credit Parties of this letter agreement and the performance
by Credit Parties of all of their respective Obligations hereunder and thereunder, have been duly and validly authorized and approved
by the Credit Parties and their respective boards of directors, as applicable, pursuant to all applicable laws and other than the
corporate action or resolutions delivered by each of the Credit Parties, as applicable, in connection with this letter agreement,
no other corporate action or consent on the part of the Credit Parties, their respective boards of directors, stockholders or any
other Person is necessary or required by the Credit Parties to execute this letter agreement to consummate the transactions contemplated
herein and therein, or perform all of the Credit Parties’ obligations hereunder and thereunder. This letter agreement has
been duly and validly executed by the Credit Parties (and the officer executing this letter agreement is duly authorized to act
and execute same on behalf of the Credit Parties) and constitute the valid and legally binding agreements of the Credit Parties,
enforceable against the Credit Parties in accordance with their respective terms.

 

Each of the Credit Parties,
jointly and severally, hereby indemnifies and holds the Buyer Indemnified Parties, and each of them, harmless from and against
any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and distributions
of any kind or nature payable by any of the Buyer Indemnified Parties to any Person, including reasonable attorneys’ and
paralegals’ fees and expenses, court costs, settlement amounts, costs of investigation and interest thereon from the time
such amounts are due at the highest non-usurious rate of interest permitted by applicable Law, through all negotiations, mediations,
arbitrations, trial and appellate levels (collectively, the “Claims”), as a result of, or arising out of, or
relating to any matters relating to this letter agreement.

 

 

 

    	 	3	 

     

    

 

 

As a material
inducement for Buyer to execute this letter agreement, each of the Credit Parties hereby releases, waives, discharges,
covenants not to sue, acquits, satisfies and forever discharges each of the Buyer Indemnified Parties and their respective
successors and assigns, from any and all Claims whatsoever in law or in equity which the Credit Parties, or any one of them,
ever had, now have, or which any successor or assign of the Credit Parties hereafter can, shall or may have against any of
the Buyer Indemnified Parties and their respective successors and assigns, for, upon or by reason of any matter, cause or
thing whatsoever related to the Transaction Documents through the date hereof. In addition to, and without limiting the
generality of foregoing, the Credit Parties further covenant with and warrant unto the Buyer and each of the other Buyer
Indemnified Parties, that there exist no claims, counterclaims, defenses, objections, offsets or other Claims against Buyer
or any other Buyer Indemnified Parties.

 

This letter agreement, the
Purchase Agreement, the Transaction Documents, the Intercreditor Agreement, the Services Agreement, the Guarantee Agreement and
the Security Agreement contain the entire understanding between and among the parties and supersedes any prior understandings and
agreements among them respecting the subject matter of this letter agreement. This letter agreement shall be governed by and construed
in accordance with the laws of the State of Nevada without regard to choice of law principles. Any dispute arising under or relating
to or in connection with this letter agreement shall be subject to the exclusive jurisdiction and venue of the State and/or Federal
courts located in Broward County, Florida. This letter agreement may be executed in any number of counterparts, each of which shall
be an original but all of which together shall constitute one and the same instrument. The parties hereby consent and agree that
if this letter agreement shall at any time be deemed by the parties for any reason insufficient, in whole or in part, to carry
out the true intent and spirit hereof or thereof, the parties will execute or cause to be executed such other and further assurances
and documents as in the reasonable opinion of the parties may be reasonably required in order more effectively to accomplish the
purposes of this letter agreement. In case any provision of this letter agreement shall be held to be invalid, illegal or unenforceable,
such provision shall be severable from the rest of this letter agreement, and the validity legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby.

 

Please indicate your agreement
with and acceptance of the terms of this letter agreement by signing in the space provided and returning this letter agreement
to our attention at the address above.

 

 

[ - signature page
follows - ]

 

 

 

 

 

    	 	4	 

     

    

 

By execution hereof, the undersigned hereby agrees
to the terms and conditions of this letter agreement.

 

Very truly yours,

 

RENNOVA HEALTH, INC.

 

 

By:
/s/ Seamus Lagan                         

Name:
Seamus Lagan

Title: Chief Executive Officer

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Chief
Executive Officer of Rennova Health, Inc., who is personally known to me to be the same person whose name is subscribed to the
foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument
as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein
set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

    	 	5	 

     

    

 

 

MEDYTOX
SOLUTIONS, INC.

 

 

By:
/s/ Seamus Lagan                            

Name:
Seamus Lagan

Title: Chief Executive Officer

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan,
the Chief Executive Officer of Medytox Solution, Inc., who is personally known to me to be the same person
whose name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she
signed and delivered the said instrument as his/her own free and voluntary act and as the free and voluntary act of said
corporation, for the uses and purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

    	 	6	 

     

    

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

HEALTH TECHNOLOGY
SOLUTIONS, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Chief Executive Officer

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

The undersigned,
a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Chief Executive Officer
of Health Technology Solutions, Inc., a Florida corporation, who is personally known to me to be the same person whose name is
subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered
the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	7	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

MEDYTOX INSTITUTE
OF LABORATORY MEDICINE, INC.

 

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Chief Executive Officer

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The undersigned,
a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Chief Executive Officer
of Medytox Institute of Laboratory Medicine, Inc., a Florida corporation, who is personally known to me to be the same person whose
name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered
the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	8	 

     

    

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

MEDICAL BILLING CHOICES INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
President

 

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The undersigned, a Notary Public in and for
the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the President of Medical Billing Choices Inc., a
North Carolina corporation, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument,
appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument as his/her own free
and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

    	 	9	 

     

    

 

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

MEDYTOX DIAGNOSTICS,
INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Chief Executive Officer

 

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Chief
Executive Officer of Medytox Diagnostics, Inc., a Florida corporation, who is personally known to me to be the same person whose
name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered
the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	10	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

MEDYTOX MEDICAL MARKETING & SALES, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary
of Medytox Medical Marketing & Sales, Inc., a Florida corporation, who is personally known to me to be the same person whose
name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered
the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

    	 	11	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

PB LABORATORIES, LLC

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The undersigned, a Notary Public in and
for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary of PB Laboratories, LLC, a
Florida limited liability company, who is personally known to me to be the same person whose name is subscribed to the
foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said
instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	12	 

     

    

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

BIOHEALTH MEDICAL LABORATORY, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary
of Biohealth Medical Laboratory, Inc., a Florida corporation, who is personally known to me to be the same person whose name is
subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered
the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

    	 	13	 

     

    

 

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

ALETHEA LABORATORIES,
INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The undersigned, a Notary Public in and for
the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary of Alethea Laboratories, Inc., a Texas
corporation, who is personally known to me to be the same person whose name is subscribed to the foregoing instrument, appeared
before me this day in person and acknowledged that he/she signed and delivered the said instrument as his/her own free and voluntary
act and as the free and voluntary act of said corporation, for the uses and purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	14	 

     

    

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

INTERNATIONAL TECHNOLOGIES, LLC

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The undersigned,
a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary of International
Technologies, LLC, a New Jersey limited liability company, who is personally known to me to be the same person whose name is subscribed
to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument
as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein
set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	15	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

EPIC REFERENCE LABS, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary
of EPIC Reference Labs, Inc., a Florida corporation, who is personally known to me to be the same person whose name is subscribed
to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument
as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein
set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

    	 	16	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

CLINLAB, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
President

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the President
of Clinlab, Inc., a Florida corporation, who is personally known to me to be the same person whose name is subscribed to the foregoing
instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument as his/her
own free and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

    	 	17	 

     

    

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR 

 

MEDICAL MIME, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary
of Medical Mime, Inc., a Florida corporation, who is personally known to me to be the same person whose name is subscribed to the
foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument
as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein
set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

    	 	18	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR

 

EPINEX DIAGNOSTICS LABORATORIES, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The undersigned,
a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary of Epinex
Diagnostics Laboratories, Inc., a California corporation, who is personally known to me to be the same person whose name is subscribed
to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered the said instrument
as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and purposes therein
set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

  

 

 

 

 

 

 

 

 

    	 	19	 

     

    

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR 

 

EPINEX DIAGNOSTICS LABORATORIES, INC.

 

 

By: /s/ Seamus
Lagan                             

Name: Seamus Lagan

Title:
Secretary

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Seamus Lagan, the Secretary
of Epinex Diagnostics Laboratories, Inc., a Nevada corporation, who is personally known to me to be the same person whose name
is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she signed and delivered
the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation, for the uses and
purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

  

 

 

 

 

 

 

 

 

 

    	 	20	 

     

    

 

 

CONSENT AND AGREEMENT

 

The undersigned
is a Guarantor, as that term is defined in that certain securities purchase agreement by and between
the Company and the Holder and, as such, the undersigned hereby consents and agrees to the payment of the amounts contemplated
in the senior secured, convertible, redeemable debenture, documents contemplated thereby and to the provisions contained therein
relating to conditions to be fulfilled and obligations to be performed by the Company pursuant to or in connection with said senior
secured, convertible, redeemable debenture to the same extent as if the undersigned were a party to said senior secured, convertible,
redeemable debenture.

 

GUARANTOR:

 

PLATINUM FINANCIAL SOLUTIONS, LLC

 

 

 

By: /s/ Sebastien
Sainsbury                          

Name: Sebastien Sainsbury

Title:
Manager

 

 

	STATE OF FLORIDA	)	 
	 	)	SS.
	COUNTY OF PALM BEACH	)	 

 

 

The
undersigned, a Notary Public in and for the said County, in the State aforesaid, DO HEREBY CERTIFY that Sebastien Sainsbury, the
Manager of Platinum Financial Solutions, LLC., a Florida limited liability company, who is personally known to me to be the same
person whose name is subscribed to the foregoing instrument, appeared before me this day in person and acknowledged that he/she
signed and delivered the said instrument as his/her own free and voluntary act and as the free and voluntary act of said corporation,
for the uses and purposes therein set forth.

 

GIVEN under my hand and notarial seal this
17th day of March, 2017.

 

 

                       /s/
Kelly Marsden                            

Notary Public

 

 

My
Commission Expires:

 

                       February
26, 2021                       

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	21	 

     

    

  

TCA GLOBAL CREDIT MASTER FUND, LP

 

 

By: TCA Global Credit Fund
GP, Ltd.,

its general partner

 

 

 

By:
/s/ Robert Press                             

Name:
Robert Press

Title: Director

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	22	 

     

    

 

 

SCHEDULE A

 

PAYMENT
AND AMORIZATION SCHEDULE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]